31 results on '"Leufkens, Hubert G.M."'
Search Results
2. Estimation of manufacturing development costs of cell-based therapies: a feasibility study
3. Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse Scenarios
4. Advanced therapy medicinal product manufacturing under the hospital exemption and other exemption pathways in seven European Union countries
5. A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature
6. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings
7. Selection of Blood, Blood Components, and Blood Products as Essential Medicines in 105 Low- and Middle-Income Countries
8. Differences in Health Technology Assessment Recommendations Among European Jurisdictions: The Role of Practice Variations
9. Unmet Medical Need: An Introduction to Definitions and Stakeholder Perceptions
10. Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe
11. Primary endpoint discrepancies were found in one in ten clinical drug trials. Results of an inception cohort study
12. Recruitment failure and futility were the most common reasons for discontinuation of clinical drug trials. Results of a nationwide inception cohort study in the Netherlands
13. Use of dipeptidyl peptidase-4 inhibitors for type 2 diabetes mellitus and risk of fracture
14. Mortality in British hip fracture patients, 2000–2010: A population-based retrospective cohort study
15. Switching from Originator Brand Medicines to Generic Equivalents in Selected Developing Countries: How Much Could Be Saved?
16. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures
17. Variable Access to Clopidogrel in a Harmonized EU Market
18. Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism and Risk and Outcome of Pneumonia
19. Impact analysis of the discontinuation of reimbursement: the case of oral contraceptives
20. Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins
21. Lithium use and the risk of fractures
22. The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks
23. International classification of diseases codes showed modest sensitivity for detecting community-acquired pneumonia
24. Methods to assess intended effects of drug treatment in observational studies are reviewed
25. Misclassification of exposure is high when interview data on drug use are used as a proxy measure of chronic drug use during follow-up
26. 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study
27. Effect of a pharmacist-led intervention on diuretic compliance in heart failure patients: a randomized controlled study
28. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias
29. Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus
30. Determinants of multiple psychotropic drug use in patients with mild intellectual disabilities or borderline intellectual functioning and psychiatric or behavioral disorders
31. Determinants of psychotropic drug usage in a general intensive care unit
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.